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Abstract 
Background: Trk receptor tyrosine kinases regulate multiple important neuronal 
processes during the development and in the adulthood. Tyrosine phosphorylation of Trk 
serves as the initial step in the Trk signaling pathway and indicates receptor´s 
autocatalytic activity. However, methods allowing simple and large-scale Trk 
phosphorylation analyses in cultured cells are lacking.  
New Method: We describe an in situ phospho-Trk ELISA (enzyme-linked 
immunosorbent assay) method where cell culture, receptor stimulation and Trk 
phosphorylation analysis are all performed on the same multiwell plate. 
Results: In situ phospho-Trk ELISA readily and specifically detects neurotrophin-
induced Trk phosphorylation in cultured cells. A proof-of-concept small molecule 
screening of a library composed of 2000 approved drugs and other bioactive compounds 
was carried out using this novel method. 
Comparison with Existing Methods: In situ phospho-Trk ELISA utilizes the principles 
and advantages of conventional sandwich ELISA in an in situ context.  
Conclusions: We describe a novel method that can be efficiently used to examine Trk 
receptor phosphorylation in cultured cells. Principally similar methods can be developed 
to examine the levels and signaling of any intracellular protein. 
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1. Introduction 
Tropomyosin-related kinases, Trks, serve as cognate receptors for 
neurotrophins: nerve growth factor (NGF) binds preferentially to TrkA, 
brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4) to 
TrkB and neurotrophin-3 (NT-3) to TrkC (Huang and Reichardt, 2001). Trk 
receptor signaling regulates several important neuronal processes and 
abnormal Trk signaling is implicated in some cancers and in numerous 
nervous system disorders, including mood disorders, neurodegenerative 
disorders and pain (Rantamäki and Castrén, 2008; Thiele et al., 2009). Thus, 
pharmacological agents affecting endogenous Trk receptor signaling would 
hold significant therapeutic potential. Supporting this concept, the therapeutic 
actions of antidepressant drugs have been associated with their ability to 
activate TrkB receptors in the brain (Saarelainen et al., 2003; Rantamäki et 
al., 2007; Rantamäki and Castrén, 2008). Furthermore, experimental Trk 
receptor agonists provide neurotrophic support and ameliorate the 
neuropathological and behavioral outcomes in animal models of 
neurodegenerative disorders (Longo and Massa, 2013).    
Upon activation, TrkB receptor is phosphorylated at specific intracellular 
tyrosine residues that further initiate intracellular signaling (Huang and 
Reichardt, 2001). TrkB phosphorylation is tightly associated with the 
receptor’s catalytic activity and is thus widely used as an indicator of TrkB 
activation (Segal et al., 1996). The main purpose of this study was to set up 
and validate an in situ ELISA (enzyme-linked immunosorbent assay) method 
that can be efficiently used to examine Trk receptor phosphorylation in 
cultured cells. In this method the cells are directly cultured (and treated) on 
multiwell plates coated with the capturing antibody and, upon cell lysis, all 
subsequent assay steps are performed in situ. We describe several conditions 
that significantly increase the sensitivity of in situ ELISA to detect ligand 
induced Trk phosphorylation. In order to further validate the developed 
method and investigate its suitability for large-scale analyses, we performed a 
semi-automated small molecule screen with the Spectrum Collection, a 
chemical library with compounds of wide range of biological activities and 
structural diversity suitable for testing de novo assays. 
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2. Materials and methods 
2.1. Reagents and chemicals 
The Spectrum Collection compounds was purchased from MicroSource 
Discovery Systems, Inc. (Gaylordsville, CT, USA) and stored at -80°C in 
DMSO stocks of 20 mM. The library consisted of 2000 compounds divided 
in three major groups: 50% drug or drug-like compounds, 30% natural 
products and 20% other bioactive compounds (for complete list visit: 
http://www.msdiscovery.com/spectrum.html). BDNF was purchased from 
Peprotech (Rocky Hill, NJ, USA), diluted in PBS (phosphate buffered saline; 
pH 7.4) containing 0.1% BSA (bovine serum albumin; Sigma Aldrich 
Finland, Helsinki, Finland) and stored in aliquots at -80°C. NGF (Promega, 
Madison, WI, USA) was kindly provided by Dr. Urmas Arumäe (University 
of Helsinki). The synthesis of 1NMPP1 (1-(1,1-dimethylethyl)-3-(1-
naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine) has been 
described previously (Sallert et al., 2009). Optacoat™ solution (catalog nro. 
C10202) was purchased from ALerCHEK Inc. (Springvale, Maine, USA). 
ProteoJET™ membrane protein extraction kit (catalog nro. K0321), 
chemiluminescence reagent (Pierce; catalog nro. 32106) and streptavidin-
HRP (catalog nro. 21126) were purchased from Thermo Fisher Scientific Oy 
(Vantaa, Finland). Trk kinase inhibitor K252a (Sigma Aldrich) was kindly 
provided by Dr. Heikki Rauvala (University of Helsinki). Detergents were 
purchased from Sigma Aldrich and prepared as 1% (all, except Brij 35) or 
0.1% solutions in buffer consisting of 137mM NaCl, 20 mM Tris, 10% 
glycerol, 50 mM NaF, 2mM Na3VO4 and protease inhibitors (Complete 
inhibitor tablets, F. Hoffmann-La Roche Ltd., Basel, Switzerland)).  
2.2. Cell culture 
MG87-trkB fibroblasts (Vesa et al., 2000) (kindly provided by Dr. Eric 
Shooter, Stanford University) were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM) (supplemented with 10% fetal calf serum, 1% 
penicillin/streptomycin, 1% L-glutamine and 400 µg/ml G418). PC12 cells 
were cultured in DMEM/F12 media (1:1; Gibco 31330-038) (supplemented 
with 10% horse serum, 5% fetal calf serum, 10 mM HEPES (pH 7.2), 5 mM 
L-glutamine, 1% penicillin/streptomycin, 20 mM sodium bicarbonate). The 
cell lines were maintained in a cell incubator (5% CO2, 37°C) until reaching 
confluence after which the cells were divided or used for experiments. 
For the primary neuronal cultures, hippocampi or cortex was dissected from 
E18 rat embryos or E16 TrkBF616A mouse embryos (kindly provided by Dr. 
David Ginty, Johns Hopkins University) and the tissue dissociated in papain 
solution (in mg: 10 DL-Cystein-HCl, 10 BSA, 250 glucose, ad 50 ml PBS 
(pH 7.4); 10 min, 37 °C). Next the cells were triturated and suspended in a 
medium containing 9.8 ml of Ca2+/Mg2+ free HBBS, 1 mM sodium pyruvate, 
10 mM HEPES (pH 7.2) and 10 µl DNAse I. The cells were plated onto poly-
L-lysine (Sigma Aldrich) coated 12-48 well culture plates at a cell density of 
130000 cells/cm2  (hippocampal) or 260000 cells/cm2 (cortical). Primary 
neurons were maintained in Neurobasal medium (supplemented with 2% 
B27, 1% penicillin/streptomycin and 1% L-glutamine) and supplemented 
with fresh medium every 3rd day. TrkBF616A mice carry a mutation near the 
ATP binding of TrkB rendering the receptor susceptible for inhibition by the 
mutation-specific kinase inhibitor 1NMPP1 (Chen et al., 2005; Sallert et al., 
2009).  
 
2.3. ELISA 
Conventional sandwich phospho-Trk ELISA was performed essentially as 
described earlier (Rantamäki et al., 2011). Specifically, cell homogenates 
(lysis volume 25-75µl) were transferred directly from culture plates into 
pre-coated (sc-11-R, Santa Cruz Biotechnology, Santa Cruz, CA, USA; 
1:500-1000 in Optacoat™; overnight at 4°C) and pre-blocked (2% 
BSA/PBS-T; 2 h at room temperature) white 96-well Optiplate™ 
(PerkinElmer Oy, Espoo, Finland) plates and 3% BSA/PBS-T (+2 mM 
Na3VO4 to inhibit tyrosine phosphatases) added ad 200 µl. After overnight 
incubation at 4°C the wells were washed with PBS-T (4×300 µl) and anti-
phosphotyrosine antibody added to the wells (in house biotinylated PY20; 
AbD Serotec, Kidlington, UK; 1:1000 in 2% BSA/PBS-T; overnight at 
4°C). Following sequential washes and HRP-coupled streptavidin antibody 
incubation (1:10000 in 2% BSA/PBS-T; O/N at 4°C) 100 µl of ECL 
substrate mix was added to the wells and luminescence measured with 
Varioskan Flash plate reader (Thermo Fisher Scientific Oy).  
For the in situ phospho-Trk ELISA, dissociated cells were directly plated 
onto UV-sterilized ELISA plates pre-coated and pre-blocked with sterile-
filtered antibody and blocking solution, respectively. Following experimental 
treatment of cells, the plates were put immediately on ice, medium discarded 
and lysis buffer applied (10-25 µl). Next, the plates were rigorously shaken in 
a cold room for 30-60 min (800 rpm, Labsystems Wellmix, Thermo Fisher 
Scientific Oy) after which 3% BSA/PBS-T (+2 mM Na3VO4 to inhibit 
tyrosine phosphatases) solution was applied ad 200 µl (96-multiwell) or ad 
50 µl (384-multiwell). After overnight incubation at 4°C, the wells were 
washed and ELISA assay continued as described above.  
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2.4. Proof-of-concept small molecule screening 
For the small molecule screening, MG87-trkB fibroblasts were cultured 
directly on 96-well ELISA plates. Next day, the cells were pre-stimulated 
with vehicle or with Spectrum Collection compounds for 15 minutes (5 µM; 
n=1; +37°C) using Biomek FXp workstation (Beckman Coulter Finland Oy, 
Helsinki, Finland) and then post-stimulated with vehicle or with BDNF (5 
ng/ml; +37°C) for another 15 minutes using Multidrop Combi (Thermo 
Fisher Scientific Oy). After the stimulations, the medium was discarded, cells 
were lysed in ProteoJET™ membrane protein extraction buffer and ELISA 
analyses run as described. Compounds regarded as hits (response to BDNF ± 
3x standard deviation (STDEV)) were re-tested in triplicates and the 
compounds that still passed the hit criteria were analyzed in a dose-response 
assay (0.25, 1, 5, 25 µM; n=3) (inhibitors with and activators without BDNF 
post-treatment).  
 
3. Results 
3.1. Conventional sandwich phospho-Trk ELISA 
We have previously developed a phospho-Trk sandwich ELISA based on 
commercial antibodies and reagents and used this assay to examine Trk 
phosphorylation in cell homogenates (Rantamäki et al., 2011). Briefly, lysed 
cell homogenates (reference lysis buffer: NP buffer) are transferred to and 
incubated on pre-blocked ELISA plates previously coated with an antibody 
directed against the intracellular domain of Trk receptors (reference antibody: 
sc-11-R, rabbit polyclonal; reference coating solution: phosphate buffered 
saline). Next, the wells are sequentially washed and incubated with 
biotinylated phospho-tyrosine antibody, streptavidin-HRP and 
chemiluminescence reagent, after which emitted light is quantified. Under 
these reference conditions, the assay readily detected BDNF-induced TrkB 
phosphorylation in MG87-trkB fibroblasts (Figure 1a), NGF-induced TrkA 
phosphorylation in PC12 cells (Figure 1b) and BDNF-induced Trk 
phosphorylation in primary mouse and rat neuronal cultures (Figure 1c-d), 
whereas no such neurotrophin-induction was seen in MG87 parental cells or 
in TrkB expressing cells pre-treated with Trk kinase inhibitors or if the 
capturing antibody was not present in the assay (Figure 1a, b-d). We further 
optimized the sampling and assay conditions by evaluating the influence of 
different lysis buffers, antibodies and coating buffers on signal-to-
background ratio (S/B) achieved with BDNF stimulation. The highest S/Bs 
were observed when the ProteoJET™ membrane protein extraction kit was 
used for the cell lysis (Figure 1e) and when the polyclonal rabbit pan-Trk 
antibody in Optacoat™ solution was used for Trk immunocapturing (Figure 
1f-g). However, small lysate levels produced significantly lower S/B than 
higher lysate levels (S/B: 50 µg < 100 µg = 200 µg) (Figure 1h). Under 
optimized assay conditions, the S/B remained unchanged for 7 minutes after 
application of chemiluminescence reagent (Figure 1i) and results obtained 
after 5 minutes were used for all described analyses.  
 
3.2. In situ phospho-Trk ELISA 
Next we sought to test whether the conventional sandwich phospho-Trk 
ELISA assay conditions can be transferred into an in situ set-up that would 
allow cell culturing, stimulation, lysis and phosphorylation analysis in the 
same plate (Figure 2a). Such in situ ELISA set-up has been previously 
utilized to examine the levels of secreted factors, including TrkB ligand 
BDNF (Balkowiec and Katz, 2000), but to the best of our knowledge not to 
examine intracellularly resident proteins such as transmembrane receptors. In 
our method, cells were directly cultured on pre-coated and pre-blocked 
ELISA plates. Following cell stimulations, the plates were immediately put 
on ice, medium discarded and cells lysed in situ by rigorous shaking in a 
small volume of lysis buffer (ProteoJET™ membrane protein extraction kit). 
Then 2 % BSA/PBS-T (supplemented with tyrosine phosphatase inhibitor 
sodium vanadate) was added to the wells and immunocapturing of Trk 
receptors was achieved during overnight incubation; after this, the wells were 
washed and ELISA assay continued as described above.  
In situ phospho-Trk ELISA readily detected BDNF-induced TrkB 
phosphorylation in MG87-trkB fibroblasts in both 96- and 384-multiwell 
formats; however, S/B was significantly higher in the former format (Figure 
2b). The method also allowed detecting small but significant BDNF-induced 
(5 ng/ml, 15 min) change in Trk phosphorylation in cultured E18 rat primary 
cortical cultures (6 days in vitro) (Vehicle: 100.00±4.70% vs. BDNF: 
157.79±2.48%; n=8-16; P<0.005, two-tailed Student t-test). 
Next we performed side-by-side analyses with conventional and in situ 
phospho-Trk ELISAs to directly compare the performances of these methods. 
Briefly, the MG87-trkB cells were grown and stimulated with BDNF in 96-
well cell-culture plates and transferred manually into 96-well ELISA plates 
or the cells were directly grown and stimulated in 96-well ELISA plates. 
Subsequent ELISA steps were performed identically thereafter. Although the 
in situ method is mechanistically more straightforward, the S/B was 
significantly better with the conventional ELISA (Figure 2c). 
 
Figure 1. Characterization and optimization of sandwich phospho-Trk ELISA (a) The assay readily 
detects BDNF-induced (5 ng/ml, 15 min) TrkB phosphorylation in fibroblasts expressing TrkB (MG87-
trkB) but not in parental cells (MG87) or if the capturing antibody is not present in the assay (n=3-
4/group) (b) NGF-induced (5 ng/ml, 15 min) TrkA phosphorylation in PC12 cells (n=3/group) (c) The 
assay readily detects BDNF-induced (5 ng/ml, 2 min) TrkB phosphorylation in E18 rat primary 
neuronal cultures whereas no signal is detected when the cultures are pretreated with kinase inhibitor 
k252a (200 nM; 15 min) (n=6/group) (d) The assay readily detects BDNF-induced (5 ng/ml, 15 min) 
TrkB phosphorylation in E16 mouse primary neuronal cultures derived from TrkBF616A mutant mice 
whereas no signal is detected when the cultures are pretreated with mutation-specific kinase inhibitor 
1NMPP1 (100 nM; 24 hours) (n=4/group) (e) The impact of tested cell lysis buffers on signal-to-
background ratio compared to reference buffer (n=5-6/group) (f) The impact of tested capture 
antibodies on signal-to-background ratio compared to reference antibody (n=3/group) (g) The impact 
of tested coating solutions on signal-to-background ratio compared to reference solution (n=3-6/group) 
(h) The impact of lysate level (50-200 µg) on signal-to-background ratio (n=3/group) (i) Signal-to-
background ratio (n=3/group) at 3, 5 and 7 minutes after addition of the chemiluminescence reagent. 
*P<0.05, **P<0.01, ***P<0.005 of vehicle or reference condition, one-way ANOVA followed by 
Newman-Keuls post hoc (a, c-h) test or Student t-test (b, i). Abbreviations: Ab=antibody, 
PBS=phosphate buffered saline, CB=carbonate buffer. 
 
3.3. Proof-of-concept small molecule screening 
We next performed a proof-of-concept small molecule screen to test the 
suitability of in situ phospho-Trk ELISA method for large-scale experimental 
studies and for drug screenings. Biomek FXp automated workstation was 
used to pre-stimulate the MG87-trkB cells with vehicle or tested compounds 
prior to submaximal BDNF (5 ng/ml, 15 min) administration. Subsequent 
steps were performed manually. Actual screen consisted of primary (with 
BDNF) and secondary (repeat with and without BDNF) screens. With this 
approach, we were able to screen for compounds that would regulate TrkB 
signaling in BDNF dependent or independent manner. A compound was 
considered as a hit if it produced a signal differing from BDNF response for a 
minimum of ±3×STDEV (of BDNF). The first set of compounds in the 
primary screen was evaluated in two independent but identical stimulation 
plates to assess the repeatability and quality of data (Figure 2d). Overall 
quality control values from the primary screen plates were as follows (value 
± STDEV): Z´ factor = 0.25±0.19, Coefficient of variation (CV) = 0.13±0.05, 
S/B = 4.15±1.31. 
Based on the primary and secondary screens, total of 26 compounds (1.3%) 
were further evaluated in a dose-response setup. Compounds that positively 
modulate TrkB phosphorylation only in the presence of BDNF were not 
found, and thus potential TrkB activators (8 compounds) were tested without 
BDNF. Since MG87-trkB cells show rather low basal phosphorylation status 
of TrkB (Rantamäki et al., 2011), potential TrkB inhibitors (18 compounds) 
were tested in the presence of BDNF. Of potential TrkB activators, only 
betamethasone valerate increased TrkB phosphorylation dose-dependently at 
doses 0.25-5 µM whereas most other compounds (amiloride, patulin, 
epoxygedunin, harmine, 7-deshydroxypyrogallin-4-carboxylic acid, 
sennoside A) regulated TrkB phosphorylation independently of concentration 
(Figure 2e and data not shown). If anything, camptothecin reduced TrkB 
phosphorylation (data not shown). Of potential inhibitors, 11 compounds 
(podofilox, tyrothricin, gramicidin, oxibendazole, podophyllin, laccaic acid 
A, picropodophyllin, tomatine, aurin tricarboxylic acid, 4-
demethylepipodophyllotoxin, 4,4-diisothiocyanostilbene-2,2-sulfonic acid) 
dose-dependently reduced BDNF-induced TrkB phosphorylation (Figure 2f 
and data not shown). Interestingly, depending on dose, 5 compounds (tannic 
acid, fenbendazole, theaflavin, plumbagin, gossypetin) produced either 
inhibition or facilitation of BDNF-induced TrkB activation (Figure 2g). Two 
compounds produced only minor changes on BDNF-induced TrkB 
phosphorylation in the dose-response set-up (albendazole, deoxysappanone) 
(data not shown).  
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Figure 2. In situ phospho-Trk ELISA and its utilization for research and compound screening (a) In situ phospho-Trk ELISA protocol (b) In situ phospho-Trk ELISA readily detects BDNF-induced (5 ng/ml, 15 
min) TrkB phosphorylation in MG87-trkB cells in 96- and 384-multiwell formats (n=2-5/group) (c) Comparison of conventional and in situ phospho-Trk ELISA methods (n=11-12/group) (d) X-Y plotted 
luminescence signal data and quality measures (Z´ value, S/B, SD) of Spectrum library compounds run in duplicate in 96-multiwell format (e) Representative Spectrum library compounds that increase TrkB 
phosphorylation in MG87-trkB cells (compounds tested without BDNF) (f) Representative Spectrum library compounds that dose-dependently inhibit BDNF-induced TrkB phosphorylation in MG87-trkB cells 
(compounds applied 15 min prior to BDNF post-treatment: 5 ng/ml, 15 min) (g) Dose-dependent effect of tannic acid, fenbendazole, theaflavin, plumbagin and gossypetin on BDNF-induced TrkB 
phosphorylation in MG87-trkB cells (compounds applied 15 min prior to BDNF post-treatment: 5 ng/ml, 15 min) *P<0.05, **P<0.01, ***P<0.005 of vehicle (b-c, e) or BDNF (f-g), Student t-test. ###<0.005, 
two-way ANOVA, followed by Newmann-Keuls post hoc test. 
 
4. Discussion 
The main aim of this study was to test whether our previously developed 
(Rantamäki et al., 2011) and further optimized conventional sandwich 
phospho-Trk ELISA (Figure 1) can be developed into an in situ format, 
i.e. a method that would allow the cells to be directly cultured, receptors 
stimulated and Trk phosphorylation assayed on the same multiwell plate. 
As a single-plate assay this approach would encompass several 
advantages over conventional sandwich ELISA. Most importantly, it 
would make unnecessary to scrape and transfer cell homogenates from 
plate to plate and therefore would reduce the time, manpower and 
resources needed for performing the analysis. Moreover, Balkowiec and 
Katz (2000, 2002) have previously developed in situ ELISA that allowed 
detecting neuronally released BDNF with higher sensitivity than the 
conventional method. The in situ phospho-Trk ELISA readily detected 
BDNF-induced phosphorylation of TrkB receptors in fibroblasts 
expressing TrkB in 96- and 384-multiwell formats, albeit the S/B ratio 
was lower in latter format, a finding that may be related to lower lysate 
amount (see Figure 1h) and thus absolute levels of TrkB protein in the 
384-well format. BDNF-induced Trk phosphorylation was also detected 
in rat primary neuronal cultures, but the S/B ratio was less than expected 
based on data obtained using conventional ELISA method and further 
optimization is needed for primary neuronal cultures employed for this 
approach. We also compared the S/B achieved by submaximal BDNF 
stimulation in conventional and in situ Trk ELISA methods. Although the 
in situ method is mechanistically more straightforward and thus readily 
allows implementation to robotics, the S/B was significantly better with 
the conventional ELISA.  
In order to further validate the developed in situ phospho-Trk method and 
investigate its suitability for large-scale analyses, including drug 
screening, we carried out semi-automated small-scale compound 
screening in 96-multiwell format. The method produced highly 
reproducible data in the screening setup. 
Although we did not primarily aim at identifying novel compounds 
targeting TrkB signaling, we found several potential inhibitors and 
activators of TrkB from the Spectrum Collection compounds, a selected 
set of drug and drug-like chemicals, natural products and other bioactive 
compounds. Importantly, some of the compounds represent a chemical or 
pharmacological class that has been previously shown to increase TrkB 
signaling (e.g. synthetic glucocorticoid betamethasone valerate 
(Jeanneteau et al., 2008), gedunin derivative epoxygedunin (Jang et al., 
2010)). Majority of potential TrkB inhibitors belong to anthelmintics 
(bendazole derivatives), antibiotics (e.g. gramicidin) or antiviral drugs 
(e.g. podophyllins). Interestingly, depending on dose, 5 compounds 
produced either inhibition or facilitation of BDNF-induced TrkB 
activation. 
In conclusion, we describe a novel method that can be used to examine 
Trk receptor phosphorylation in cultured cells directly plated on 
antibody-coated multiwell plates. Principally similar methods can be 
developed to examine the levels and signaling of any cellular protein. 
Indeed, our preliminary studies indicate that the in situ ELISA approach 
can be utilized for the detection of phosphorylated Tau (data not shown), 
a microtubule assembly protein whose hyperphosphorylation has been 
implicated in the pathophysiology of neurodegenerative disorders. 
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